1,828 Shares in IQVIA Holdings Inc. $IQV Purchased by Quarry LP

Key Points

• Quarry LP invested $322,000 in IQVIA Holdings Inc., purchasing 1,828 shares during the first quarter, as confirmed in its Form 13F filing with the SEC.
• Multiple large investors have increased their stakes in IQVIA, with Pacer Advisors Inc. raising its stake by over 5,036% during the same period, highlighting strong institutional interest in the company.
• IQVIA reported a 5.3% increase in revenue to $4.02 billion for the last quarter, exceeding analysts' expectations, and its earnings per share were $2.81, beating the consensus estimate.

Quarry LP acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,828 shares of the medical research company's stock, valued at approximately $322,000.

Several other large investors also recently modified their holdings of the stock. Canada Pension Plan Investment Board lifted its holdings in shares of IQVIA by 7.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock worth $810,069,000 after purchasing an additional 312,807 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after purchasing an additional 798,534 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of IQVIA by 26.8% in the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock worth $253,695,000 after purchasing an additional 304,258 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of IQVIA by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock worth $251,852,000 after purchasing an additional 40,699 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of IQVIA by 13.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company's stock worth $273,766,000 after purchasing an additional 167,057 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent research reports. JPMorgan Chase & Co. cut their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Robert W. Baird increased their target price on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Barclays increased their target price on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Mizuho increased their target price on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Finally, UBS Group raised their price objective on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $229.86.

IQVIA Stock Performance

Shares of NYSE IQV traded up $0.31 during mid-day trading on Wednesday, reaching $184.05. 1,191,973 shares of the company's stock were exchanged, compared to its average volume of 1,204,917. The firm has a market capitalization of $31.29 billion, a price-to-earnings ratio of 26.64, a price-to-earnings-growth ratio of 2.09 and a beta of 1.32. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $250.46. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a 50-day moving average price of $178.75 and a two-hundred day moving average price of $167.71.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the prior year, the firm earned $2.64 EPS. The company's revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.